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Abstract Lymphotactin-XCL1 is a chemokine
produced mainly by activated CD8? T-cells and
directs migration of CD4? and CD8? lymphocytes
and natural killer (NK) cells. We expressed human
lymphotactin (LTN) by the lactic-acid bacterium
Lactococcus lactis. Biological activity of LTN was
confirmed by chemo-attraction of human T-cells by
chemotaxis demonstrating, for the first time, how this
chemokine secreted by a food-grade prokaryote
retains biological activity and chemoattracts T lym-
phocytes. This strain thus represents a feasible
well-tolerated vector to deliver active LTN at a
mucosal level.
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Introduction
Chemokines, the largest family of cytokines, cause
leukocyte mobilization through chemotaxis at sites of
antigenic challenge or lesions. Lymphotactin (LTN),
the only member of the C subfamily of chemokines, is
mainly secreted by activated T lymphocytes and it
chemoattracts CD4? and CD8? lymphocytes as well
as natural killer (NK) cells (Hedrick et al. 1997). This
chemokine plays an important role in maintaining the
integrity of the epithelium and in mucosal immune
responses. Previous studies revealed that the intrana-
sal administration of LTN resulted in the
enhancement of the mucosal and systemic antibody
response through help provided by Th1- and Th2-type
cells (Lillard et al. 1999).
Moreover, this chemokine has some antitumor
activity and, when expressed in engineered myeloma
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cells, resulted in tumor regression in mice. This effect
was assumed to be mediated by CD4? and CD8?
cells and neutrophils expressing the XCR1 receptor,
the receptor for LTN (Cairns et al. 2001). Another
approach to use LTN as an enhancer of immune
responses was with the manipulation of dendritic cells
(DCs) for the expression of this chemokine. The
administration of the DCs expressing LTN caused a
potent adjuvant effect for peptide delivery causing
specific antitumor immunity in mice (Cao et al. 1998).
Our goal was to create an innocuous and safe
vector to produce, but mostly to deliver, LTN in vivo.
In recent years, the lactic-acid bacterium L. lactis has
been used as an efficient vector to express heterol-
ogous proteins of medical and therapeutic interest
(Wells and Mercenier 2008). The intranasal immuni-
zation with strains of this food-grade bacterium has
resulted in the generation of specific humoral and
cytotoxic immune responses against infectious and
chronic diseases (Braat et al. 2006; Hanniffy et al.
2007; Wells and Mercenier 2008). Because of these
promising results using this microorganism, we
genetically manipulated a strain of L. lactis to
express and secrete human lymphotactin (huLTN).
Here we demonstrate how this L. lactis-secreted LTN
remains biologically active and able to chemoattract
T lymphocytes by chemotaxis. This is the first report
that demonstrates the biological activity of huLTN
secreted by a food-grade lactic acid bacterium.
Materials and methods
Bacterial strains and growth conditions
Lactococcus lactis NZ9000 (Kuipers et al. 1997) was
grown aerobically in M17 medium (DIFCO) supple-
mented with 1% glucose (GM17) at 30C without
agitation. Escherichia coli DH5a was grown in Luria–
Bertani (LB) medium at 37C with aeration and
vigorous shaking. Unless otherwise indicated, con-
struction were first established in E. coli and then
transferred to L. lactis by electrotransformation (Holo
and Nes 1989). Clones were selected by addition of
100 lg ampicillin/ml or 10 lg chloramphenicol/ml for
E. coli and 10 lg chloramphenicol/ml for L. lactis.
PCR was done using Vent DNA polymerase (New
England Biolabs) according to the manufacturer’s
instructions using a programmable thermal controller.
Harvest and culture of macrophages
Human macrophages were isolated from freshly
drawn blood by using Ficoll–Hypaque (Histopaque-
1077, Sigma). The layer of mononuclear cells was
recovered, washed with PBS, and cultured for 3 h in
RPMI 1640 medium supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (FBS) and then
incubated at 37C in a 5% CO2. Adherent cells
(macrophages) were recovered by removing the
culture medium. Macrophages were seeded into
6-well plates (Costar) at 5 9 106 cells/ml in com-
plete RPMI-1640 medium (10% v/v heat-inactivated
FBS, 1% penicillin–streptomycin solution, and 1%
HEPES buffer) stimulated with 20 mg lipopolysac-
charides/ml (LPS B from E. coli 026:B6, Sigma) and
incubated at 37C in a 5% CO2 for 5 h.
Human cDNA preparation
The total RNA from 5 9 106 cells of LPS-stimulated
human macrophages was isolated using TRizol
reagent (Gibco) according to the manufacturer’s
instructions. The concentration and integrity of
RNA was determined by measuring absorbance at
260 nm and analyzed by formaldehyde–agarose gel
electrophoresis. The first strand cDNA was synthe-
sized from 1 lg total RNA by SuperscriptTM II
reverse transcriptase (Gibco) and oligo (dT) 12–18
primer.
Protein extraction from L. lactis
Cell and cell-free medium fractions were prepared
separately. Samples were processed from 1.35 ml of
cultures of L. lactis. Cell pellets were obtained by
centrifugation at 21000g at 4C for 5 min. Cell
pellets were then resuspended in 100 ll lysis buffer
containing 25% (w/v) sucrose, 1 mM EDTA, 50 mM
Tris/HCl, pH 8.0, lysozyme (10 mg/ml) comple-
mented with 1 mM PMSF to avoid proteolysis and
10 mM DTT and incubated at 37C for 1 h. Samples
were kept at -20C before loading onto gel.
The cell-free medium samples were treated with
1 mM PMSF and 10 mM DTT to avoid proteolysis.
Proteins were precipitated adding 150 ll of 100%
trichloroacetic acid (TCA) to 1.35 ml cell-free
medium (TCA at 10% w/v) and incubated on ice
for 10 min followed by centrifugation at 21000g at
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4C for 15 min. The pellet was resuspended in 50 ll
of 50 mM NaOH and 50 ll of 29 SDS-PAGE
loading buffer (100 mM Tris/HCl, pH 6.8, 200 mM
DTT, 4% v/v SDS, 0.1% Bromophenol Blue, and
10% v/v glycerol).
SDS-PAGE and western blotting
Samples were electrophoresed in 12% polyacrylamide
gels. Immunodetection was done using polyclonal
anti-lymphotactin (Santa Cruz) as a primary antibody
and protein-G horseradish-peroxidase conjugate
(BioRad). SuperSignal West Pico Chemiluminescent
Substrate (Pierce) was used as recommended by the
suppliers.
Lymphocyte culture
Human peripheral blood lymphocytes were isolated
from donor whole blood by centrifugation on Ficoll–
Hypaque (Histopaque-1077 Sigma) according to
manufacturer’s instructions. After washing three
times with RPMI 1640 medium (Gibco), the cells
were cultured in RPMI 1640 medium supplemented
with 10% human serum (Sigma) and 200 U human
interleukin 2/ml (Santa Cruz Biotechnologies) at
37C in a 5% CO2 for 12 days. Cell density was kept
between 1 and 3 9 106 cells/ml.
Chemotaxis assay and flow cytometry
Cell migration was measured in 5 lm diameter
pore-size cellulose-nitrate membranes (Whatman)
using a Boyden chemotaxis chamber. Cell-free
medium from wild type and recombinant L. lactis
cultures were sterilized by filtration through a
0.22 lm filter (Millex, Millipore) and loaded into
the lower compartment of Boyden chamber for
chemotaxis. Lymphocytes (105 cells) in RPMI 1640
medium were loaded into the upper compartment.
Chemotaxis was allowed to occur for 1 h at 37C.
Migrated cells were counted by a fluorescence-
activated cell-sorting (FACS) flow cytometer. The
aqueous phase from the lower compartment of
chambers was gently recovered and centrifuged.
The resulting cell pellet was suspended in PBS and
incubated for 10 min with human anti-CD3 FITC
(BD Biosciences Pharmingen, San Diego, USA),
washed with PBS, and counted with an FACS
sorting cytometer. All chemotaxis assays were done
in triplicate. Complement-activated serum was pre-
pared from fresh human serum by addition of 25 mg
zymosan (Sigma) per ml serum and incubated at
37C for 1 h. Statistical analysis was done using the
Tukey test.
Results and discussion
Construction of an inducible system for LTN
secretion by L. lactis
Lymphotactin is a chemokine produced by leukocytes
upon stimulation. To obtain a DNA sequence coding
for huLTN, we first constructed a cDNA from human
macrophages stimulated with LPS. The DNA
sequence coding for the mature moiety was PCR
amplified from this human cDNA with the following
oligonucleotides: LptnHP9rw: (50-TATGCATCAGT
AGGGAGTGAAATCTCA-30) and reverse primer
(LptnHLBfw: 50-CTAGCCAGTCAGGGTCACAGC
TGT-30), which generated a NsiI restriction site
(indicated in bold) to manipulate the fragment for
future cloning. The 298 bp amplicon was directly
cloned into the pCR2.1 vector (Invitrogen) and
named pCR2.1-huLTN.
For the generation of the plasmid responsible for
regulation of expression and secretion of LTN in
L. lactis, the plasmid pCR2.1-huLTN was digested
with NsiI–EcoRI releasing the fragment coding for
LTN and subcloned into the pSEC-E7 vector digested
with the same enzymes. The final construct was
named pSEC-huLTN. This strategy permitted the
fusion in-frame of the DNA sequence coding for LTN
with the signal peptide from the usp45 (SPUsp45), the
most secreted protein of L. lactis (van Asseldonk
et al. 1990), and placed under the regulation of the
well-characterized nisin-inducible promoter (PnisA)
(Fig. 1).
Finally our construction was introduced into the
L. lactis strain NZ9000 carrying the regulatory genes
nisR and nisK (de Ruyter et al. 1996) by electro-
transformation as previously described (Holo and Nes
1989). Recombinant strains carrying the final con-
struct were selected by resistance to chloramphenicol
and named NZSEC:huLTN. All plasmids were
endonuclease-characterized and sequenced for DNA
integrity.
Biotechnol Lett (2009) 31:215–220 217
123
Secretion of LTN by L. lactis is efficient
To evaluate the functionality and efficiency of the
system for secretion of LTN, three transformants
(NZSEC:huLTN) were induced with nisin for just 1 h
to allow LTN expression and then analyzed by
Western blot using polyclonal anti-lymphotactin
antibodies. Protein extractions were made separately
for cell and cell-free medium fractions.
Western blot analysis of samples from the cell-free
medium from the induced cultures revealed a single
band of 10 kDa, the expected molecular mass of LTN,
indicating that that protein corresponded to LTN
secreted by L. lactis (Fig. 2). No degradation or
incomplete forms of the LTN were detected, showing
an efficient secretion of the chemokine by L. lactis. To
evaluate the functionality of the inducible system and
to determine if the system remained completely shut-
down in the absence of the inducer (nisin), we analyzed
samples from non-induced cultures of these same
recombinant strains. No signal was detected in any of
the non-induced samples, showing how the expression
of the LTN is strictly regulated by the nisin-inducible
system, where in the absence of nisin, the expression of
LTN is completely turned off (Fig. 2). No signal was
detected in either of the cell fractions from induced and
non-induced cultures (data not shown). Samples from
the cell-free medium from wild-type L. lactis were
included as controls. As expected, no signal for LTN
was detected (Fig. 2).
Secreted amount of LTN by L. lactis
To estimate the relative amount of LTN secreted by
L. lactis, cultures from recombinant NZSEC:huLTN
at an OD600 nm of 0.6 were induced for 1 h followed
by protein extraction from the cell-free medium as
before. Serial dilutions were compared against fixed
amounts of human recombinant lymphotactin (RnD
Systems) by western blot analysis. The undiluted
extract in Fig. 3, which has the highest intensity,
corresponds to protein precipitated from 675 ll
cell-free medium from an induced culture of
NZSEC:huLTN. Analysis of band intensities with
computer software (Phoretix 1D, Nonlinear dynam-
ics) indicates that our recombinant L. lactis secretes
at least 590 ng of LTN per ml of culture. This result
demonstrates how this strain of L. lactis is able
to secrete more than 500 ng huLTN protein in just
1 h/ml of culture.
PnisA RBS SPUsp45 LTN Ter
Fig. 1 Schematic representation of LTN expression system for
production and secretion by L. lactis. The scheme represents
the regulatory system to express huLTN by L. lactis, controlled
by inducible promoter Pnis (Pnis), and using the ribosome
binding site (RBS) and signal peptide of the of Usp45 protein
(SPusp45). The final gray bar (from left to right) represents a
rho-independent trpA transcription terminator. (Not to scale)
LTN10 kD 
M         -  +  -    +   -   + 
W NZSEC:huLTN 
Fig. 2 Efficient secretion of huLTN by L. lactis. Three
different clones from recombinant L. lactis (NZSEC:huLTN)
were analyzed by Western blot for secretion of huLTN.
Cell-free medium samples of induced (?) and non-induced (-)
cultures. WT, cell-free medium from wild type strain. M,
protein molecular marker
100  50         UD  1:2  1:4  1:8  1:16 
ng
LTN10 kD 
NZSEC:huLTN 
Fig. 3 Semiquantitative analysis of LTN secreted by L. lactis.
Cultures of recombinant L. lactis (NZSEC:huLTN) grown
were induced with 10 ng/ml of nisin for 1 h. The cell-free
medium samples were processed and serial dilutions from the
total extract from 1:2 to 1:16 were prepared. Samples and two
fixed amounts of pure recombinant LTN (50 and 100 ng) were
analyzed by Western Blot using a specific anti-lymphotactin
antibody. Undiluted sample (UD) represents the amount of
LTN in 675 ll from a L. lactis culture induced for 1 h
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Biological activity of L. lactis-secreted LTN
Lymphotactin is a glycosylated chemokine able to
direct migration of T lymphocytes and NK cells
(Dorner et al. 1997; Lillard et al. 1999). Because we
achieved the expression of this LTN in L. lactis, our
next step was to determine the biological activity of
this L. lactis-secreted chemokine. We measured the
ability to chemoattract human T lymphocytes by the
L. lactis-secreted LTN in a chemotaxis assay. For this
we added 105 cells of activated T lymphocytes to the
upper compartment of the chemotaxis chamber and
cell-free medium from cultures of L. lactis to the
bottom compartment. Chemotaxis was allowed to
occur for 1 h at 37C and then the attracted cells to
the bottom of the chamber were recovered. After
centrifugation, the cells were washed with PBS and
incubated with human anti-CD3? and counted with a
FACS flow cytometer. The cell counts showed that
the LTN present in medium from induced cultures of
recombinant strain NZSEC:huLTN induced chem-
oattraction of more than 15,000 T cells (Fig. 4),
indicating the ability of this chemokine secreted by a
gram positive bacterium to chemoattract human T
lymphocytes. The cell-free medium from a culture of
wild-type L. lactis and PBS were used as negative
controls and did not attract significant amounts of
cells. Complement-activated serum was used as a
positive control (Fig. 4).
These results demonstrate for the first time the
expression and secretion of a C subfamily chemokine
of human origin by L. lactis, biologically active, able
to cause chemoattraction of human T lymphocytes
(Fig. 4).
Antecedents have demonstrated the use of L. lactis
as a biological vector to deliver antigens and
cytokines at mucosal surfaces to cause humoral and
cytotoxic immune responses (Wells and Mercenier
2008). Here we report a novel strain of L. lactis able
to secrete a biologically active antitumor chemokine.
This food-grade bacterium represents a feasible
well-tolerated vector intended to be used in live
organisms to deliver huLTN at a mucosal level.
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